Polyvinylpyrrolidone capped silver nanoparticles enhance the autophagic clearance of Acinetobacter baumannii from human pulmonary cells
Source abstract
Abstract
Acinetobacter baumannii, an opportunistic pathogen has shown an upsurge in its multi-drug resistant isolates. OmpA of A. baumannii induces incomplete autophagy and apoptosis in host cells. Various therapeutic alternatives are under investigation against A. baumannii. Here, the major emphasis has been laid on comparing the efficacy of AgNP with different capping agents. OmpA targeted lead, Ivermectin capped AgNP (IVM-AgNP) has been compared with the antibacterial polyvinylpyrrolidone capped AgNP (PVP-AgNP) for their role in the modulations of host autophagy. Upregulation of p62 and LC3B confirmed by real-time PCR analysis indicated an increased autophagic flux upon the treatment with AgNPs. The elongation and closure of autophagic vacuoles was also supported by upregulated Atg genes (Atg4, Atg3, Atg5) in A. baumannii infected cells after treatment with AgNP. Autophagic flux increased on treatment with PVP-AgNP as suggested by the rise in mcherryLC3B fluorescence in A549 cells treated with PVP-AgNP as compared to the GFP-LC3B of IVM-AgNP. This suggests that PVP-AgNP treatment more effectively promotes the elongation and maturation stages of autophagy by increasing autophagic flux. These results indicate that capped AgNPs have the efficiency to revert the incomplete autophagy induced by A. baumannii back to normal autophagic levels.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Vibrio bacteria research studies · Antibiotic Resistance in Bacteria
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (49)
Show source-provided references
1. Wong D, et al. Clinical and pathophysiological overview of acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409–47.10.1128/CMR.00058-16 ↗
2. Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb Genom. 2019. https://doi.org/10.1099/mgen.0.000306.10.1099/mgen.0.000306 ↗
3. Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:2475067.10.1155/2016/2475067 ↗
4. Piperaki ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951–7.10.1016/j.cmi.2019.03.014 ↗
5. Weinberg SE, et al. Control and management of multidrug resistant Acinetobacter baumannii: a review of the evidence and proposal of novel approaches. Infect Prev Pract. 2020;2(3):100077.10.1016/j.infpip.2020.100077 ↗
6. Rumbo C, et al. The Acinetobacter baumannii Omp33-36 porin is a virulence factor that induces apoptosis and modulates autophagy in human cells. Infect Immun. 2014;82(11):4666–80.10.1128/IAI.02034-14 ↗
7. An Z, et al. Acinetobacter baumannii outer membrane protein A induces HeLa cell autophagy via MAPK/JNK signaling pathway. Int J Med Microbiol. 2019;309(2):97–107.10.1016/j.ijmm.2018.12.004 ↗
8. Zhao D, et al. Outer membrane protein a in Acinetobacter baumannii induces autophagy through mTOR signalling pathways in the lung of SD rats. Biomed Pharmacother. 2021;135:111034.10.1016/j.biopha.2020.111034 ↗
9. Kulshrestha M, Tiwari M, Tiwari V. Bacteriophage therapy against ESKAPE bacterial pathogens: current status, strategies, challenges, and future scope. Microb Pathog. 2024;186:106467.10.1016/j.micpath.2023.106467 ↗
10. Mulani MS, et al. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10:539.10.3389/fmicb.2019.00539 ↗
11. Yeh YC, et al. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front Chem. 2020;8:286.10.3389/fchem.2020.00286 ↗
12. Sharma S, Tiwari M, Tiwari V. Therapeutic strategies against autophagic escape by pathogenic bacteria. Drug Discov Today. 2021;26(3):704–12.10.1016/j.drudis.2020.12.002 ↗
13. Yetisgin AA, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020. https://doi.org/10.3390/molecules25092193.10.3390/molecules25092193 ↗
14. Assolini JP, et al. Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications. Parasitol Res. 2017;116(6):1603–15.10.1007/s00436-017-5458-2 ↗
15. Sanfelice RAS, et al. Biogenic silver nanoparticles (AgNp-Bio) reduce Toxoplasma gondii infection and proliferation in HeLa cells, and induce autophagy and death of tachyzoites by apoptosis-like mechanism. Acta Trop. 2021;222:106070.10.1016/j.actatropica.2021.106070 ↗
16. Nayak PS, et al. Silver nanoparticles fabricated using medicinal plant extracts show enhanced antimicrobial and selective cytotoxic propensities. IET Nanobiotechnol. 2019;13(2):193–201.10.1049/iet-nbt.2018.5025 ↗
17. Slavin YN, et al. Novel lignin-capped silver nanoparticles against multidrug-resistant bacteria. ACS Appl Mater Interfaces. 2021;13(19):22098–109.10.1021/acsami.0c16921 ↗
18. Auda IG, et al. In-vivo and in-vitro anti-Acinetobacter baumannii activity of citrate-capped silver nanoparticles. Nano Biomed Eng. 2021;13(3):229–39.10.5101/nbe.v13i3.p229-239 ↗
19. Tiwari V, Tiwari M, Solanki V. Polyvinylpyrrolidone-capped silver nanoparticle inhibits infection of carbapenem-resistant strain of Acinetobacter baumannii in the human pulmonary epithelial cell. Front Immunol. 2017;8:973.10.3389/fimmu.2017.00973 ↗
20. Shahverdi AR, et al. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine. 2007;3(2):168–71.10.1016/j.nano.2007.02.001 ↗
21. Deshpande LM, Chopade BA. Plasmid mediated silver resistance in Acinetobacter baumannii. Biometals. 1994;7(1):49–56.10.1007/BF00205194 ↗
22. Xu L, et al. Silver nanoparticles: synthesis, medical applications and biosafety. Theranostics. 2020;10(20):8996–9031.10.7150/thno.45413 ↗
23. Jovic M, et al. The early endosome: a busy sorting station for proteins at the crossroads. Histol Histopathol. 2010;25(1):99–112.
24. Birgisdottir ÅB, Johansen T. Autophagy and endocytosis - interconnections and interdependencies. J Cell Sci. 2020. https://doi.org/10.1242/jcs.228114.10.1242/jcs.228114 ↗
25. Zhang J, et al. Systematic investigation on the intracellular trafficking network of polymeric nanoparticles. Nanoscale. 2017;9(9):3269–82.10.1039/C7NR00532F ↗
26. Porter GC, et al. Endocytosed silver nanoparticles degrade in lysosomes to form secondary nanoparticle structures during expression of autophagy genes in osteogenic cells. Nanomedicine. 2021;33:102355.10.1016/j.nano.2020.102355 ↗
27. Kang J, et al. Silver nanoparticles present high intracellular and extracellular killing against Staphylococcus aureus. J Antimicrob Chemother. 2019;74(6):1578–85.10.1093/jac/dkz053 ↗
28. Parra-Millán R, et al. Intracellular trafficking and persistence of Acinetobacter baumannii requires transcription factor EB. mSphere. 2018. https://doi.org/10.1128/mSphere.00106-18.10.1128/mSphere.00106-18 ↗
29. Tiwari M, et al. Assessment of molecular mechanism of gallate-polyvinylpyrrolidone-capped hybrid silver nanoparticles against carbapenem-resistant Acinetobacter baumannii. ACS Omega. 2020;5(2):1206–13.10.1021/acsomega.9b03644 ↗
30. Liu J, et al. Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells. 2019. Biosci Rep. https://doi.org/10.1042/BSR20192489.10.1042/BSR20192489 ↗
31. Lim LE, et al. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother. 2013;57(2):1040–6.10.1128/AAC.01696-12 ↗
32. Omansen TF, et al. In-vitro activity of avermectins against mycobacterium ulcerans. PLoS Negl Trop Dis. 2015;9(3):e0003549.10.1371/journal.pntd.0003549 ↗
33. Ashraf S, et al. In vitro activity of ivermectin against Staphylococcus aureus clinical isolates. Antimicrob Resist Infect Control. 2018;7:27.10.1186/s13756-018-0314-4 ↗
34. Coelho PP, et al. Endosomal LC3C-pathway selectively targets plasma membrane cargo for autophagic degradation. Nat Commun. 2022;13(1):3812.10.1038/s41467-022-31465-3 ↗
35. Tiwari V, et al. Anti-bacterial activity of polyvinyl pyrrolidone capped silver nanoparticles on the carbapenem resistant strain of Acinetobacter baumannii. J Nanomed Nanotechnol. 2014;5(246):10.4172.
36. Tiwari V, et al. Comparative anti-bacterial activity of differently capped silver nanomaterial on the carbapenem sensitive and resistant strains of Acinetobacter baumannii. J Nanomed Nanotechnol. 2015;6(5):1.
37. El-Naggar NE-A, et al. Green synthesis of chitosan nanoparticles, optimization, characterization and antibacterial efficacy against multi drug resistant biofilm-forming Acinetobacter baumannii. Sci Rep. 2022;12(1):19869.10.1038/s41598-022-24303-5 ↗
38. Nie D, et al. Outer membrane protein A (OmpA) as a potential therapeutic target for Acinetobacter baumannii infection. J Biomed Sci. 2020;27(1):26.10.1186/s12929-020-0617-7 ↗
39. Hitchman A, et al. The effect of environmentally relevant conditions on PVP stabilised gold nanoparticles. Chemosphere. 2013;90(2):410–6.10.1016/j.chemosphere.2012.07.041 ↗
40. Kora AJ, Rastogi L. Enhancement of antibacterial activity of capped silver nanoparticles in combination with antibiotics, on model gram-negative and gram-positive bacteria. Bioinorg Chem Appl. 2013;2013:871097.10.1155/2013/871097 ↗
41. Setyawati MI, et al. The influence of lysosomal stability of silver nanomaterials on their toxicity to human cells. Biomaterials. 2014;35(25):6707–15.10.1016/j.biomaterials.2014.05.007 ↗
42. Gnanadhas DP, et al. Interaction of silver nanoparticles with serum proteins affects their antimicrobial activity in vivo. Antimicrob Agents Chemother. 2013;57(10):4945–55.10.1128/AAC.00152-13 ↗
43. Quevedo AC, et al. Mechanisms of silver nanoparticle uptake by embryonic zebrafish cells. Nanomaterials (Basel). 2021. https://doi.org/10.3390/nano11102699.10.3390/nano11102699 ↗
44. Kelley LA, et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015;10(6):845–58.10.1038/nprot.2015.053 ↗
45. Ko J, et al. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 2012;40:W294-7.10.1093/nar/gks493 ↗
46. Bhattacharya A, Tejero R, Montelione GT. Evaluating protein structures determined by structural genomics consortia. Proteins. 2007;66(4):778–95.10.1002/prot.21165 ↗
47. Yan Y, et al. The HDOCK server for integrated protein–protein docking. Nat Protoc. 2020;15(5):1829–52.10.1038/s41596-020-0312-x ↗
48. Jiang S, et al. Bacterial lipoprotein plays an important role in the macrophage autophagy and apoptosis induced by Salmonella typhimurium and Staphylococcus aureus. Open Life Sci. 2023;18(1):20220739.10.1515/biol-2022-0739 ↗
49. Verma P, et al. Potentiate the activity of current antibiotics by naringin dihydrochalcone targeting the AdeABC efflux pump of multidrug-resistant Acinetobacter baumannii. Int J Biol Macromol. 2022;217:592–605.10.1016/j.ijbiomac.2022.07.065 ↗